EP1012175A1 - Peptide presentant une affinite vis-a-vis du facteur de coagulation viii - Google Patents

Peptide presentant une affinite vis-a-vis du facteur de coagulation viii

Info

Publication number
EP1012175A1
EP1012175A1 EP98946452A EP98946452A EP1012175A1 EP 1012175 A1 EP1012175 A1 EP 1012175A1 EP 98946452 A EP98946452 A EP 98946452A EP 98946452 A EP98946452 A EP 98946452A EP 1012175 A1 EP1012175 A1 EP 1012175A1
Authority
EP
European Patent Office
Prior art keywords
peptide
peptides
factor viii
seq
affinity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP98946452A
Other languages
German (de)
English (en)
Other versions
EP1012175B1 (fr
Inventor
Alois Jungbauer
Roman Necina
Djuro Josic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Octapharma AG
Original Assignee
Octapharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7842252&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1012175(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Octapharma AG filed Critical Octapharma AG
Publication of EP1012175A1 publication Critical patent/EP1012175A1/fr
Application granted granted Critical
Publication of EP1012175B1 publication Critical patent/EP1012175B1/fr
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Definitions

  • the present invention relates to a peptide with binding affinity for factor VIII, a carrier material to which the peptide according to the invention is bound, a diagnostic agent containing the peptide according to the invention, use of the peptide for labeling, identification or purification of factor VIII and a method for producing the invention Peptide synthesized in a liquid or solid phase system.
  • Affinity chromatography (Yannis Chonis; Process Affinity Chromatography, in Separation Processes in Biotechnology, Ed. JA Asenjo, pages 401 to 494, Marcel Dekker, New.) Is a method that is well established in the prior art for the purification of particularly complex structures such as proteins York 1990; SR Narayanon, Preparative affinity chromatography of proteins, J. Chromatogr. A, 658 (1994) 237 to 258).
  • Huang, Ping Y. et al. describe in "Bioorganic & Medicinal Chemistry", Vol. 4, No. 5, pp. 699 to 708, 1996 the use of peptides which can be used for the affinity purification of von Willebrand factor.
  • the von Willebrand factor is a component in the blood plasma and plays an important role in the stabilization of factor VIII.
  • Factor VIII itself is also a valuable plasma component, which is of particular therapeutic interest, namely for eliminating disorders of the blood coagulation cascade, in which factor VIII plays an important role.
  • the preparation of factor VIII from blood plasma continues to play an important role.
  • Numerous methods for the purification of factor VIII by means of chromatographic methods are known.
  • Methods of immunoaffinity chromatography are also used, in which antibodies against factor VIII are immobilized on a support and factor VIII-containing samples are brought into contact with this support material, so that factor VIII can be isolated from the samples in question by immunoaffinity reactions.
  • a disadvantage of the latter method is in particular that the antibodies are relatively large molecules which occupy a large part of the surface of the carrier material and thus result in a capacity limitation.
  • contamination can occur through bleeding of the antibodies from the separation column.
  • the aim of the present invention is to provide a material with which a cleaning of factor VIII is facilitated.
  • the peptides according to the invention have the structure
  • R 1 NH 2 or a peptide, preferably having no more than 20 amino acid units
  • R 2 COOH or a peptide
  • X an at least tripeptide, preferably hepta- to dodecapeptide, which has an affinity bond with factor VIII.
  • R 1 thus indicates the N-terminal end of a peptide represented by structural element X
  • R 2 indicates the carboxyl end of a peptide defined by X.
  • the structural elements also refer to the salts in this regard and derivatives such as N-modified derivatives or carboxy-terminally modified derivatives.
  • amino acids which can be used to form the peptide according to the invention include both the naturally occurring amino acids and non-proteinogenic amino acids. These are regularly a-amino acids. Possible structural variants of the amino acids are those which have modifications in the side chain, cyclic peptides, branched or mixotropic peptides.
  • the structural element X has at least three amino acids which are linked by peptides, the structural element X is preferably a hepta, octa or nonapeptide, preferably an octape peptide to dodecapeptide, which is distinguished by binding to factor VIII.
  • the structural element X is preferably a hepta, octa or nonapeptide, preferably an octape peptide to dodecapeptide, which is distinguished by binding to factor VIII.
  • Particularly preferred are the octapeptides, which are identified in the sequence listing with the sequence identification numbers Seq. ID. No. 1 to Seq. ID. No. 94 are explicitly mentioned.
  • the particularly preferred octapeptides of the structure shown in Seq. ID. No. 1 to 94 are able to bind factor VIII specifically.
  • the latter peptides bind to human or recombinant factor VIII.
  • the last named peptides have a striking affinity for both recombinant factor VIII and factor VIII, which was produced from plasma.
  • the octapeptides with the Seq. Id. No. 61, 66, 71, 72, 76, 77, 78, 81 to 84, 89 and 90 are characterized in isolation by binding to pdFVIII (factor VIII from plasma).
  • the peptide binds with the Seq. Id. No. 61 no recombinant factor VIII.
  • the octapeptides with the Seq. Id. No. 56 to 58, 66, 68, 71, 72, 76 to 78, 81 to 84, 87 to 90 bind recombinant factor VIII, the octapeptides having the Seq. Id. No.
  • 66, 71, 72, 76 to 78, 81 to 84 and 89 and 90 also bind factor VIII isolated from plasma. According to the invention, particular preference is given to the octapeptides with the Seq. Id. No. 66, 72, 78, 84, 89 and 90.
  • the peptides with the Seq. Id. No. 66 and 90 to 94 are particularly suitable for the affinity chromatography of rFVIII (recombinant factor VIII) and the peptides 66, 72 and 91 to 94 for the affinity chromatography of pdFVIII.
  • these peptides can also be used to produce a carrier material according to the invention.
  • This carrier material has a surface with attached peptides according to the invention and is the subject of claims 8 to 9.
  • the peptides according to the invention are preferably chemically bound to the surface of the carrier material according to the invention.
  • Chemical bonding means both covalent and ionic, hydrophobic and / or complex interactions.
  • the carrier material preferably consists of inorganic or organic, in particular polymeric material.
  • the polymeric materials which are generally usable per se in the chromatography of biopolymers can be used.
  • the peptides according to the invention are preferably bound to the surface of the carrier material by spacers (arms). These spacers are known to the person skilled in the art. The spacers are preferably such that they do not interfere with the affinity binding between factor VIII and the peptides in the chromatographic separation process.
  • Spacers usually consist of linear, low-molecular hydrocarbon chains which are equipped with functional groups at both ends.
  • a summary of the state of the art can be found at G.T. Hermanson, A.K .. Mallia and P.K. Smith; Immobilized Affinity Ligand Techniques, Academic Press, Inc., San Diego, New York, Boston, London, Sydney, Tokyo, Toronto 1992.
  • One end is bound to a solid support while the other end is used to bind the peptide ligand.
  • the hydrocarbon chains can also be modified.
  • DADPA diaminodipropylamine
  • succinic acid succinic acid (as anhydride)
  • 6-aminocaproic acid 1, 3-diamino-2-propanol
  • 1, 6-diaminohexane DH
  • ethylenediamine EDA
  • amino acids, peptides, sugars and other polyols can also act as spacers.
  • Iminodiacetic acid or lysine can also be used as a spacer.
  • lysine is bound to a support as Fmoc-Lys (Fmoc) -OH or Fmoc- (Lys) - (Boc) -OH.
  • Fmoc Fmoc-Lys
  • Lis Fmoc- (Lys) - (Boc) -OH.
  • protective groups lysine with carboxyl terminus is bound to the support.
  • Selective cleavage of the protective groups gives free amino groups to which at least one peptide can be bound.
  • the amino groups of the lysine can also be blocked by other protective groups.
  • polymers with a hydrophilic surface for example so-called tentacle materials, can be used as chromatographic supports.
  • the immobilization of the peptides according to the invention on compact porous disks and / or membranes, each preferably with a hydrophilic surface, is also advantageous.
  • Corresponding devices are described in WO-A-96/06158. Due to the fact that the peptides according to the invention interact with factor VIII, the peptide compounds according to the invention are suitable as diagnostic agents for factor VIII.
  • the diagnostic agent according to the invention therefore contains at least one peptide according to the invention, or a carrier material according to the invention, to which at least one peptide according to the invention is bound, and optionally auxiliaries.
  • the peptide according to the invention is marked to indicate that a peptide according to the invention has reacted with factor VIII.
  • a radioactive label for example, or a label using fluorescent ligands, the avidin / streptavidin system or enzymes which can cause color reactions, as are generally known in the ELISA technique, can serve as the label.
  • the peptides according to the invention are suitable for labeling, identifying or purifying factor VIII.
  • the peptides according to the invention can be prepared by methods which are well established in peptide chemistry, in particular by Merrifield solid-phase synthesis or in the liquid phase.
  • the chromatography system ProSys Biosepra Inc. Marlborough, USA was used for all chromatographic experiments.
  • PBS buffer pH 7.0 was used as an equilibration and washing buffer.
  • a 0.1 M glycine buffer pH 3.0 was used for the elution.
  • the flow rate was 0.1 ml / min in all experiments.
  • Lyophilized factor VIII from plasma was dissolved in 11 ml of distilled water to a concentration of 90 units / ml. 4 ml of each was applied at a flow rate of 0.1 ml / min. The affinity carriers were then washed with PBS buffer pH 7.0 until the UV signal (280 nm) reached the baseline again. The bound material was eluted with 0.1 M glycine pH 3.0. The collected fractions were analyzed using SDS-Page under reducing conditions and Western blot. In this way, peptides and the ßAla-ßAla blank were examined for their ability to bind factor VIII from the octavi preparation.
  • Binding was VIII of recombinant factor using Kogena- te ® (Bayer) studied. 400 ⁇ l of the preparation (200 units) were diluted with 1,400 ⁇ l of distilled water and then applied to the affinity support at a flow rate of 0.1 ml / min. The washing was again carried out with PBS, pH 7.0 and the subsequent elution with 0.1 M glycine, pH 3.0. The fractions were analyzed using SDS-Page under reducing conditions and Western blot.
  • the run and eluates of all runs were collected and analyzed by SDS-PAGE under reducing conditions and Western blot. 4 to 20% Tris-Glycine gels from Novex were used for the separation. The samples were treated with SDS sample buffer (1.5 M Tris HC1 pH 8.45, 1.2 ml glycerol, 0.4 g SDS, 0.1% Coomassie Blue, 0.1% phenol red per 10 ml), and 5% ⁇ -mercaptoethanol was added and the mixture was incubated at 4 ° C. overnight. After separation, the gels were stained with silver and scanned.
  • SDS sample buffer 1.5 M Tris HC1 pH 8.45, 1.2 ml glycerol, 0.4 g SDS, 0.1% Coomassie Blue, 0.1% phenol red per 10 ml
  • the gels were electroblotted constantly on a nitrocellulose membrane at 200 mA for two hours. The membrane was then blocked with PBS + 3% BSA for two hours. After washing with PBS buffer, the anti-FVIII antibody mixture (Chemicon International Inc., MAB038, Sera-Lab MAS 530, MAS 531, MAS 532) was added for two hours. After washing with PBS, alkaline phosphatase (1: 1000, Sigma Chemicals, A-3438) was incubated for one hour with anti-mouse IgG. The development was carried out with 0.1 M Tris, pH 9.2, NBT and BCIP.
  • the peptides Seq. Id. No. 55 to 90 were immobilized on a membrane. After equilibration with PBS buffer pH 7.0, a membrane with factor VIII Scripti ® (240 units in 10 ml PBS pH 7.0 with 1% BSA), another with Kogenate ® (250 U in 10 ml PBS, pH 7.0 with 1% BSA) and one incubated only with PBS, pH 7.0 with 1% BSA for two hours. The membranes filled with the peptides were carefully washed with PBS buffer pH 7.0 and then the anti-FVIII antibodies (Chemicon International Inc., MAB038, Sera-Lab MAS 530, MAS 531, MAS 532) were added for one hour.
  • the anti-FVIII antibodies Chemicon International Inc., MAB038, Sera-Lab MAS 530, MAS 531, MAS 532
  • the control membrane immobilized with ⁇ Ala- ⁇ Ala, binds the recombinant factor VIII only very weakly.
  • the Western blot of the eluate is positive.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP98946452A 1997-09-13 1998-09-12 Peptide presentant une affinite vis-a-vis du facteur de coagulation viii Revoked EP1012175B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19740310A DE19740310A1 (de) 1997-09-13 1997-09-13 Peptid mit Affinität zu Gerinnungsfaktor VIII
DE19740310 1997-09-13
PCT/EP1998/005822 WO1999014232A1 (fr) 1997-09-13 1998-09-12 Peptide presentant une affinite vis-a-vis du facteur de coagulation viii

Publications (2)

Publication Number Publication Date
EP1012175A1 true EP1012175A1 (fr) 2000-06-28
EP1012175B1 EP1012175B1 (fr) 2003-01-08

Family

ID=7842252

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98946452A Revoked EP1012175B1 (fr) 1997-09-13 1998-09-12 Peptide presentant une affinite vis-a-vis du facteur de coagulation viii

Country Status (9)

Country Link
EP (1) EP1012175B1 (fr)
CN (1) CN1203088C (fr)
AT (1) ATE230758T1 (fr)
BR (1) BR9812435A (fr)
DE (2) DE19740310A1 (fr)
DK (1) DK1012175T3 (fr)
ES (1) ES2190605T3 (fr)
HK (1) HK1026436A1 (fr)
WO (1) WO1999014232A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR638801A0 (en) * 2001-07-13 2001-08-09 Life Therapeutics Limited Factor viii separation
GB0508435D0 (en) * 2005-04-26 2005-06-01 Sandoz Ag Organic compounds
AU2011253661B2 (en) * 2005-04-26 2013-06-13 Boehringer Ingelheim Rcv Gmbh & Co Kg Production of recombinant proteins by autoproteolytic cleavage of a fusion protein
DK1874825T3 (da) * 2005-04-26 2010-07-05 Sandoz Ag Affinitetsligander
JP2009518345A (ja) 2005-12-07 2009-05-07 テフニーシェ ウニヴェルジテート ミュンヘン 因子ｖｉｉｉおよび因子ｖｉｉｉ様タンパク質に対する小型ペプチドおよびペプチド模倣物の親和性リガンド
JP2011524170A (ja) * 2008-06-16 2011-09-01 チラリックス ビー．ブイ． ペプチジルアルギニンデイミナーゼ（ｐａｄ）阻害剤
CN101303356B (zh) * 2008-06-20 2012-07-18 许贤豪 一种筛选适用于检测和纯化凝血第八因子的单克隆抗体的方法
CN103506080A (zh) * 2012-06-19 2014-01-15 汪志友 一种用于分离纯化凝血因子viii的介质及其制备方法
CN106046148B (zh) * 2016-06-27 2019-08-23 新乡医学院 一种利用肽配基亲和纯化凝血因子viii的方法
CN110448719B (zh) * 2019-06-28 2020-05-22 浙江大学 一种促进凝血的丝素-多肽电纺膜及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3869584D1 (de) * 1987-04-03 1992-04-30 Hermann Hofmann Verfahren zum kompostieren von organischen stoffen und vorrichtung zur durchfuehrung dieses verfahrens.
US5043429B1 (en) * 1987-05-01 1997-10-14 Scripps Research Inst Protein fragments containing factor VIII binding domain of von willebrand factor
US5200510A (en) * 1987-06-16 1993-04-06 Zymogenetics, Inc. Method for purifying factor viii:c, von willebrand factor and complexes thereof
DE19521313A1 (de) * 1995-06-12 1996-12-19 Max Planck Inst Fuer Physiolog Verfahren zur affinitätschromatographischen Aufreinigung von Faktor VIII
FR2748028B1 (fr) * 1996-04-30 1998-08-14 Lab Francais Du Fractionnement Peptides derives du facteur von willebrand et leur utilisation comme anticoagulant

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9914232A1 *

Also Published As

Publication number Publication date
ATE230758T1 (de) 2003-01-15
CN1203088C (zh) 2005-05-25
ES2190605T3 (es) 2003-08-01
HK1026436A1 (en) 2000-12-15
EP1012175B1 (fr) 2003-01-08
DE19740310A1 (de) 1999-04-01
DK1012175T3 (da) 2003-04-28
DE59806878D1 (de) 2003-02-13
BR9812435A (pt) 2000-09-26
CN1278829A (zh) 2001-01-03
WO1999014232A1 (fr) 1999-03-25

Similar Documents

Publication Publication Date Title
Pouny et al. Interaction of D-amino acid incorporated analogs of pardaxin with membranes
EP0783522B1 (fr) PEPTIDES DE LA SEQUENCE DE hPTH (1-37)
DE2717741C2 (fr)
EP0456152A2 (fr) Peptide-amides, leur procédé de préparation et les agents contenant ces peptides inhibiteurs de la coagulation de fibrine/thrombine
EP0799890A2 (fr) Mutants inactifs de la partie centrale de la streptavidine
EP1012175B1 (fr) Peptide presentant une affinite vis-a-vis du facteur de coagulation viii
EP1481004A2 (fr) Peptide de liaison a la streptavidine
WO1998038218A1 (fr) PROCEDE PERMETTANT D'OBTENIR UN FACTEUR DE VON WILLEBRAND (vWF) OU UN COMPLEXE FACTEUR VIII
JPH06510028A (ja) ランチオニン架橋ペプチド
Brown et al. Affinity purification of synthetic peptides and proteins on porous graphitised carbon
EP0152612B1 (fr) Détermination de fibrine avec anticorps spécifiques à fibrine
DE60226324T2 (de) Glykopeptide, deren herstellung und verwendung in der diagnose oder behandlung von multipler sklerose
DE3727610A1 (de) Synthetische peptide, gegen diese gerichtete antikoerper und deren verwendung
DE102007025291A1 (de) Verfahren und Immunabsorbentien zur spezifischen Detektion und Absorption Zöliakie- und Dermatitis herpetiformis assoziierter Antikörper
DE3014582C2 (fr)
EP0815141B1 (fr) Anticorps agissant a l'encontre d'un polypeptide fusionne comportant une partie histidine
DE60033783T2 (de) Regulatorische/entfaltende peptide von ezrin
EP0446797B1 (fr) Peptides synthétiques comportant des séquences du facteur VIIa et leur utilisation
SI20528A (sl) Peptid z afiniteto do strjevalnega faktorja VIII
DE102010054767A1 (de) Verfahren zur Trennung, Aufkonzentration und/oder Reinigung von (Blut)Plasmaprotein, Viren oder Virenbestandteilen
FLINN et al. Synthesis and biological characterisation of a series of iberiotoxin analogues
DE4404168A1 (de) Hirudinderivate und Verfahren zu deren Herstellung
DE10208877B4 (de) Verwendung eines Streptavidin- Bindungspeptides
CA2301959A1 (fr) Peptide ayant une affinite pour le facteur viii
Geraghty et al. Biological activity and receptor binding properties of some analogues of pQDPFLRFamide

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000309

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

17Q First examination report despatched

Effective date: 20020311

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE

REF Corresponds to:

Ref document number: 230758

Country of ref document: AT

Date of ref document: 20030115

Kind code of ref document: T

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: SCHMAUDER & PARTNER AG PATENTANWALTSBUERO

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: GERMAN

REF Corresponds to:

Ref document number: 59806878

Country of ref document: DE

Date of ref document: 20030213

Kind code of ref document: P

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20030400292

Country of ref document: GR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

Effective date: 20030512

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2190605

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PLBQ Unpublished change to opponent data

Free format text: ORIGINAL CODE: EPIDOS OPPO

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

26 Opposition filed

Opponent name: BAXTER AKTIENGESELLSCHAFT

Effective date: 20031006

NLR1 Nl: opposition has been filed with the epo

Opponent name: BAXTER AKTIENGESELLSCHAFT

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20040902

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20040913

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20040917

Year of fee payment: 7

Ref country code: FR

Payment date: 20040917

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20040922

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20040923

Year of fee payment: 7

Ref country code: FI

Payment date: 20040923

Year of fee payment: 7

Ref country code: ES

Payment date: 20040923

Year of fee payment: 7

Ref country code: CH

Payment date: 20040923

Year of fee payment: 7

Ref country code: BE

Payment date: 20040923

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20040924

Year of fee payment: 7

Ref country code: GR

Payment date: 20040924

Year of fee payment: 7

Ref country code: DK

Payment date: 20040924

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20041011

Year of fee payment: 7

PLAY Examination report in opposition despatched + time limit

Free format text: ORIGINAL CODE: EPIDOSNORE2

RDAF Communication despatched that patent is revoked

Free format text: ORIGINAL CODE: EPIDOSNREV1

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050912

PLBC Reply to examination report in opposition received

Free format text: ORIGINAL CODE: EPIDOSNORE3

RDAG Patent revoked

Free format text: ORIGINAL CODE: 0009271

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT REVOKED

27W Patent revoked

Effective date: 20050917

GBPR Gb: patent revoked under art. 102 of the ep convention designating the uk as contracting state

Free format text: 20050917

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

NLR2 Nl: decision of opposition

Effective date: 20050917

REG Reference to a national code

Ref country code: SE

Ref legal event code: ECNC